BRPI0912475B8 - compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica - Google Patents

compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica

Info

Publication number
BRPI0912475B8
BRPI0912475B8 BRPI0912475A BRPI0912475A BRPI0912475B8 BR PI0912475 B8 BRPI0912475 B8 BR PI0912475B8 BR PI0912475 A BRPI0912475 A BR PI0912475A BR PI0912475 A BRPI0912475 A BR PI0912475A BR PI0912475 B8 BRPI0912475 B8 BR PI0912475B8
Authority
BR
Brazil
Prior art keywords
compounds
kinase inhibitors
producing
pharmaceutical composition
inhibitors
Prior art date
Application number
BRPI0912475A
Other languages
English (en)
Inventor
Guoqing Chen Paul
Original Assignee
Advenchen Laboratories Llc
Guoqing Chen Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advenchen Laboratories Llc, Guoqing Chen Paul filed Critical Advenchen Laboratories Llc
Publication of BRPI0912475A2 publication Critical patent/BRPI0912475A2/pt
Publication of BRPI0912475A8 publication Critical patent/BRPI0912475A8/pt
Publication of BRPI0912475B1 publication Critical patent/BRPI0912475B1/pt
Publication of BRPI0912475B8 publication Critical patent/BRPI0912475B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

compostos como inibidores de quinase, por tratar a invenção dos compostos da formula i, dos processos para a sua preparação, e das composições farmacêuticas que os incorporam como ingredientes ativos, métodos para o tratamento de estados de doenças associados à angiogêneses, tais como cânceres associados com proteínas tirosina quinases, e à sua utilização como medicamentos para a produção de inibidores de efeitos de redução de tirosina quinase em animais de sangue quente tais como humanos.
BRPI0912475A 2008-08-19 2009-08-13 compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica BRPI0912475B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8990808P 2008-08-19 2008-08-19
US61/089,908 2008-08-19
US12/540,300 US8211911B2 (en) 2008-08-19 2009-08-12 Compounds as kinase inhibitors
US12/540,300 2009-08-12
PCT/US2009/053779 WO2010021918A1 (en) 2008-08-19 2009-08-13 Compounds as kinase inhibitors

Publications (4)

Publication Number Publication Date
BRPI0912475A2 BRPI0912475A2 (pt) 2018-01-09
BRPI0912475A8 BRPI0912475A8 (pt) 2018-03-20
BRPI0912475B1 BRPI0912475B1 (pt) 2020-12-29
BRPI0912475B8 true BRPI0912475B8 (pt) 2021-05-25

Family

ID=41696956

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912475A BRPI0912475B8 (pt) 2008-08-19 2009-08-13 compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica

Country Status (13)

Country Link
US (1) US8211911B2 (pt)
EP (1) EP2312950B1 (pt)
JP (1) JP5585892B2 (pt)
KR (1) KR101727757B1 (pt)
CN (1) CN102159078B (pt)
AU (1) AU2009282962B2 (pt)
BR (1) BRPI0912475B8 (pt)
CA (1) CA2733250C (pt)
ES (1) ES2617678T3 (pt)
IL (1) IL210573A (pt)
MX (1) MX2010011813A (pt)
NZ (1) NZ590954A (pt)
WO (1) WO2010021918A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) * 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN114805352B (zh) * 2015-07-11 2023-09-15 南京爱德程医药科技有限公司 作为pi3k/mtor抑制剂的吡咯并吡啶取代的稠合喹啉化合物
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
CN110357856B (zh) * 2018-04-09 2021-02-26 新发药业有限公司 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法
CN115850237B (zh) * 2018-07-24 2025-03-28 正大天晴药业集团股份有限公司 一种吲哚衍生物的合成方法
CN108864050B (zh) * 2018-07-25 2019-12-10 上海博璞诺科技发展有限公司 一种合成安罗替尼及其盐酸盐的方法
CN113045559B (zh) * 2021-03-15 2022-05-20 贵州医科大学 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
PT1154774E (pt) * 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
WO2004018430A1 (ja) 2002-08-23 2004-03-04 Kirin Beer Kabushiki Kaisha ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
MXPA06002256A (es) 2003-08-29 2006-05-17 Pfizer Naftaleno carboxamidas y sus derivados utiles como agentes anti-angiogenicos.
AU2004309166B2 (en) 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
GEP20084439B (en) 2004-01-23 2008-07-25 Amgen Inc Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
WO2005097134A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
WO2005114219A2 (en) 2004-05-20 2005-12-01 Wyeth Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
AU2006277742B2 (en) 2005-08-08 2010-08-26 Pfizer Inc. Salts and polymorphs of a VEGF-R inhibitor
US7977346B2 (en) 2006-01-17 2011-07-12 Guoqing Paul Chen Spiro compounds and methods of use
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors

Also Published As

Publication number Publication date
AU2009282962A8 (en) 2011-11-10
CA2733250A1 (en) 2010-02-25
JP2012500269A (ja) 2012-01-05
AU2009282962B2 (en) 2015-10-08
BRPI0912475A8 (pt) 2018-03-20
JP5585892B2 (ja) 2014-09-10
KR20110044749A (ko) 2011-04-29
CN102159078A (zh) 2011-08-17
US20100048599A1 (en) 2010-02-25
AU2009282962A1 (en) 2010-02-25
EP2312950A4 (en) 2012-10-24
WO2010021918A8 (en) 2011-01-27
CA2733250C (en) 2016-06-21
EP2312950B1 (en) 2016-11-30
CN102159078B (zh) 2014-05-21
BRPI0912475B1 (pt) 2020-12-29
EP2312950A1 (en) 2011-04-27
US8211911B2 (en) 2012-07-03
WO2010021918A1 (en) 2010-02-25
IL210573A0 (en) 2011-03-31
IL210573A (en) 2016-05-31
BRPI0912475A2 (pt) 2018-01-09
ES2617678T3 (es) 2017-06-19
KR101727757B1 (ko) 2017-04-17
MX2010011813A (es) 2010-12-01
NZ590954A (en) 2012-11-30

Similar Documents

Publication Publication Date Title
BRPI0912475B8 (pt) compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
BR112022007612A2 (pt) Inibidores de raf quinases
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EA201000341A1 (ru) 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
BR112016030730A8 (pt) composto
ATE534292T1 (de) Spiroverbindungen und anwendungsverfahren dafür
BRPI0622054B8 (pt) composto e composição farmacêutica
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
BR112017019790A2 (pt) terapia combinada otimizada e uso da mesma para tratar câncer e doença autoimune
BRPI0822162A8 (pt) método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
BRPI0808764B8 (pt) compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BRPI0418351A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112018011607A2 (pt) composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF